2015—2017年成都市第五人民医院门诊降糖药的使用情况分析

Analysis on usage of antidiabetic drugs in Department of Outpatient of Chengdu Fifth People's Hospital from 2015 to 2017

目的了解2015—2017年成都市第五人民医院门诊降糖药的应用情况,为临床用药提供参考。方法采用世界卫生组织(WHO)推荐的以限定日剂量(DDD)为指标的分析方法,对2015—2017年成都市第五人民医院门诊降糖药的品种、销售金额、用药频度(DDDs)、日均费用(DDC))和排序比(B/A)等进行统计分析。结果注射类和口服类降糖药的用药金额和DDDs逐年增长;注射类的销售金额稳居第1位,口服类用药总金额排序首位的是α-糖苷酶抑制剂,其次是格列奈类胰岛素促泌剂;阿卡波糖片的销售金额和DDDs值排序始终居首位,其次是瑞格列奈片。胰岛素各品种总的销售金额和DDDs值得排名基本稳定,B/A值均接近1.00,DDC值均小于15元。结论 2015—2017年成都市第五人民医院门诊口服降糖药的临床使用基本合理,阿卡波糖片的使用量超过指南中一线用药二甲双胍片。

Objective To investigate the utilization of antidiabetic drugs in Department of Outpatient of Chengdu Fifth People’s Hospital from 2015 to 2017,and provide reference for clinical application.Methods The breed,consumption sum,frequency of drug use(DDDs),defined daily cost(DDC),and drug sequence ratio(B/A)of antidiabetic drugs in Department of Outpatient of Chengdu Fifth People’s Hospital from 2015 to 2017 were analyzed retrospectively by defined daily doses(DDD)recommended by WHO.Results Consumption sum and DDDs of injectable and oral antidiabetic drugs increased year by year.Sales amount of injectable antidiabetic drugs were ranked the first.Sales amount and DDDs ofα-glucosidaseinhibitor in oral antidiabetic drugs were ranked the top,followed by non-sulfonylurea secretagogues.Sales amount and DDDs of Acarbose Tablets were always ranked the first,followed by Repaglinide Tablets in the second place.The sequence of sales amount and DDDs of various types of insulin had no obvious floating,and the rankings were basically stable.Among them,sales amount of insulin analogs were ranked the first.The B/A ratio of injectable were close to 1.00,and DDDs of various types of insulin less than 15.Conclusion The clinical use of antidiabetic drugs in Department of Outpatient of Chengdu Fifth People’s Hospital from 2015 to 2017 is basically reasonable.The use of Acarbose Tablets significantly exceeds the recommended first-line metformin in the guidelines.